Announcements Trials
Browse Landscape

Phase

Phase NA 6Phase 3 3

Status

Completed 3Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Breast Neoplasms 592Neoplasms 296Carcinoma, Non-Small-Cell Lung 284Prostatic Neoplasms 266Colorectal Neoplasms 213Multiple Myeloma 181Lung Neoplasms 149Neoplasm Metastasis 139Leukemia, Myeloid, Acute 125Leukemia 120Lymphoma 114Lymphoma, Follicular 113Stomach Neoplasms 105Lymphoma, Non-Hodgkin 102Colonic Neoplasms 98Ovarian Neoplasms 96Rectal Neoplasms 95Precursor Cell Lymphoblastic Leukemia-Lymphoma 94Uterine Cervical Neoplasms 93Head and Neck Neoplasms 92Leukemia, Lymphocytic, Chronic, B-Cell 91Pain 90Carcinoma, Hepatocellular 86Pancreatic Neoplasms 81Melanoma 78Lymphoma, Large B-Cell, Diffuse 77Papillomavirus Infections 68Recurrence 66Squamous Cell Carcinoma of Head and Neck 64Parkinson Disease 4, Autosomal Dominant Lewy Body 62

Interventions

Corticotropin-Releasing Hormone 2Losartan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Completed × Edema × Clear all
NCT01805453 2020-05-08

ASTER

Assistance Publique - Hôpitaux de Paris

Phase 3 Completed
80 enrolled
CNS

Edema, Glioblastoma

NCT00088166 2014-08-13

XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors

Celtic Pharma Development Services

Phase 3 Completed
200 enrolled 17 charts
CNS

Astrocytoma, Brain Edema, Brain Neoplasms, Edema

NCT00226655 2012-08-31

An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies

Celtic Pharma Development Services

Phase 3 Completed
112 enrolled 8 charts
CNS

Astrocytoma, Brain Edema, Brain Neoplasms, Edema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡